Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors

The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cell...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Harada, Takeshi, Ozaki, Shuji, Oda, Asuka, Tsuji, Daisuke, Ikegame, Akishige, Iwasa, Masami, Udaka, Kengo, Fujii, Shiro, Nakamura, Shingen, Miki, Hirokazu, Kagawa, Kumiko, Kuroda, Yoshiaki, Kawai, Shigeto, Itoh, Kohji, Yamada-Okabe, Hisafumi, Matsumoto, Toshio, Abe, Masahiro
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2013
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873421/
https://ncbi.nlm.nih.gov/pubmed/24386306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0083905
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares